1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola
Sep 11, 2018•1 hr 3 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast